Related Experiment Videos
Infectious mononucleosis-like response in common marmosets infected with Epstein-Barr virus
Abstract:
Callithrix jacchus marmosets infected with Epstein-Barr virus (EBV) with or without concurrent treatment with cyclosporin A (CySA) remained healthy. Five marmosets given virus alone developed lymphocytosis and heterophile antibody. Antibody to EBV capsid antigens (VCA) appeared and remained at titers of 1:40-1:80 from 15 weeks onward. Two animals produced antibody to the R component of early antigens (EA) from six weeks onward. Five CySA-treated EBV-infected marmosets showed no increase in total lymphocyte counts; only two developed heterophile antibody. Four developed persistent antibody to the EA-R component. All developed antibody to VCA, and mean titers were higher than in animals given EBV alone. Antibody to VCA also appeared in animals given EBV into Waldeyer's ring. Because these responses to EBV resemble those of humans, C. jacchus may provide a useful model for exploring the potential of cofactors in inducing EBV-associated malignancy.
Insights
Marmosets infected with Epstein-Barr virus (EBV) remained healthy, with some developing antibodies. Cyclosporin A treatment altered EBV immune responses in these non-human primates, suggesting a potential model for EBV-associated diseases.
Area of Science:
- Virology
- Immunology
- Primate Models
Background:
- Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus.
- Understanding EBV pathogenesis and associated malignancies is crucial.
- Non-human primate models are valuable for studying human viral diseases.
Purpose of the Study:
- To investigate the immune response of Callithrix jacchus marmosets to Epstein-Barr virus (EBV) infection.
- To evaluate the effect of cyclosporin A (CySA) treatment on EBV infection in marmosets.
- To assess the utility of marmosets as a model for EBV-associated diseases.
Main Methods:
- Infection of marmosets with EBV, with or without concurrent CySA treatment.
- Monitoring of clinical health, lymphocyte counts, and antibody production (heterophile antibody, anti-VCA, anti-EA-R).
- Administration of EBV via different routes (e.g., into Waldeyer's ring).
Main Results:
- EBV-infected marmosets remained healthy, with some developing lymphocytosis and antibodies to EBV capsid antigens (VCA) and early antigens (EA-R).
- CySA treatment in EBV-infected marmosets resulted in no increase in lymphocyte counts and altered antibody responses, with higher VCA titers.
- Antibody to VCA was observed in all EBV-infected marmosets, including those treated with CySA or infected via Waldeyer's ring.
Conclusions:
- Callithrix jacchus marmosets exhibit immune responses to EBV that resemble human responses.
- CySA influences the immune response to EBV in marmosets.
- Marmosets serve as a relevant model for studying EBV, including the role of cofactors in EBV-associated malignancy.